— Know what they know.
Not Investment Advice

ATTBF OTC

Abattis Bioceuticals Corp.
1W: -96.7% 1M: -96.7% 3M: -96.7% YTD: -96.7% 1Y: -96.7% 3Y: -90.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 46 · $14334 mcap · 476M float · 0.0047% daily turnover

Balance Sheet Trends

Total Assets
$19M +69.0% ▲
5Y CAGR: +26.7%
Total Liabilities
$9M +2734.8% ▲
5Y CAGR: +46.8%
Shareholders Equity
$11M -3.6% ▼
5Y CAGR: +22.3%
Cash & Investments
$2M -73.6% ▼
5Y CAGR: +12.1%
Total Debt
$2M +0.0% ▲
Net Debt
-$450K +88.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2015FY2016FY2017FY2018FY2019
— Assets —
Cash$165K$38K$526K$4M$2M
Short-Term Investments$93K$0$0$5M$383K
Cash & ST Investments$258K$38K$526K$9M$2M
Net Receivables$39K$767$128K$0$155K
Inventory$0$0$0$30K$268K
Other Current Assets$0$0$0$0$20K
Total Current Assets$349K$91K$679K$10M$4M
Property, Plant & Equip.$166K$149K$530K$725K$757K
Goodwill & Intangibles$1M$1M$0$0$15M
Long-Term Investments$0$0$0$213K$51K
Other Non-Current Assets$2K$2K$2K$0$0
Total Non-Current Assets$1M$1M$532K$938K$16M
Total Assets$2M$1M$1M$11M$19M
— Liabilities —
Accounts Payable$717K$608K$231K$224K$220K
Short-Term Debt$0$0$0$0$1M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$19K$36K$0$0$3M
Total Current Liabilities$1M$1M$439K$303K$5M
Long-Term Debt$0$31K$0$0$0
Other Non-Current Liab.$0$0$0$0$4M
Total Non-Current Liabilities$0$31K$0$0$4M
Total Liabilities$1M$1M$439K$303K$9M
— Equity —
Common Stock$0$15M$22M$109M$114M
Retained Earnings-$14M-$15M-$23M-$100M-$102M
Accumulated OCI$122K$1M-$178K$2M-$186K
Total Stockholders Equity$861K$671K$2M$11M$11M
Total Liabilities & Equity$2M$1M$1M$11M$19M
— Key Metrics —
Total Debt$0$31K$0$0$2M
Net Debt-$165K-$8K-$526K-$4M-$450K
Total Investments$93K$0$0$5M$434K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms